Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors | Novartis | Ongoing | ABL001 (asciminib) | 3 | CABL001A2301 | KFSH&RC-R |
| "A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3" | Eli Lilly | Completed | Mirikizumab | 3 | I6T-MC-AMAP | King Fahad Specialist Hospital (Dammam) |
| A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3204 | KAUH-J |
| "A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" | MSD | Ongoing | Ertugliflozin | 3 | MK-8835-059-00 | KSH |
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial | Celgene | Completed | Luspatercept (ACE 536) | 3 | ACE-536-B-THAL-001 | KKUH |
| A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease. | Eli Lilly | Terminated | Prasugrel | 3 | H7T-MC-TADO | KAUH-J |
| A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE | Pfizer | Completed | PF-06651600 | 2a | B7981007 | NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah) |
| "A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease " | Janssen-Cilag International NV | Ongoing | Guselkumab | 2 | CNTO1959CRD3001 | KAMC |
| A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care | Kaleido Biosciences | Completed | KB195 | 2 | K020-218 | KKUH |
| A Phase 1/2 Open-label Clinical Study of hLB-001 Gene Therapy in Pediatric Patients With Methylmalonic Acidemia Characterized by MMUT Mutations | Logic Bio Therapeutics | Ongoing | AAV-hHA-hMUT | 1 | LB001-001 | King Abdulaziz Medical City NG (Riyadh) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.